The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
FDA clears investigational new drug application for CD20-directed CAR T-cell therapy MB-106
On May 10, 2021, it was announced that the U.S. Food and Drug Administration (FDA) cleared an investigational new drug (IND) application to evaluate MB-106 for relapsed or refractory (R/R) CD20+ B-cell malignancies.
This decision allows the initiation of a phase I/II multicenter study that will investigate the safety, tolerability, and efficacy of MB-106 in patients with R/R B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia (CLL). The study is due to begin by the end of 2021.
MB-106 is a CD20-directed, autologous chimeric antigen receptor (CAR) T-cell therapy designed to express a third-generation CAR, that was created at the Fred Hutchinson Cancer Research Center.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content